trending Market Intelligence /marketintelligence/en/news-insights/trending/UGx74j4746v2i-UgH4Devg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

PDL BioPharma raises common stock, note repurchase authorization to $275M

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

PDL BioPharma raises common stock, note repurchase authorization to $275M

PDL BioPharma Inc.'s board has authorized the repurchase of up to $275 million of common stock and convertible notes, an increase of $75 million from the prior authorization.

PDL, which acquires, manages, and commercializes commercial-stage pharmaceutical assets and late-clinical-stage pharmaceutical products, initially authorized $200 million for the buyback of shares and notes.

On Dec. 13, the company said it had entered a private agreement to exchange 80% of its outstanding 2.75% convertible senior notes due Dec. 2021 and Dec. 2024 for $98 million in cash and 13.4 million of its common shares.

The cash and common stock to be distributed by PDL in this exchange will utilize about $143.8 million of the original $200 million authorization.